Anthranilic Acid

Anthranilic Acid

SCHEMBL12475896

N#Cc1ccccc1-c1ccccc1.Nc1ccccc1C(=O)O

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.50
HNF4A P41235 1/20 0.46
BCAT2 O15382 1/20 0.45
PTPN5 P54829 1/20 0.43
ALDH1A1 P00352 2/20 0.43
FABP3 P05413 1/20 0.43
FABP4 P15090 1/20 0.43
FABP5 Q01469 1/20 0.43
HSD17B10 Q99714 1/20 0.43
GRIA2 P42262 1/20 0.43
GRIA4 P48058 1/20 0.43
BRS3 P32247 1/20 0.42
GAA P10253 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GALR3 O60755 1/20 0.42
HPGD P15428 1/20 0.42
FFAR1 O14842 1/20 0.41
AKR1B1 P15121 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Anthranilic Acid SCHEMBL9173369 0.82 BCAT2 (0.60) HNF4ABCAT2ALDH1A1FABP3FABP4
Benzoic Acid SCHEMBL8919114 0.79 ESR2 (0.58) ESR2PTPN5GRIA2GRIA4FFAR1
SCHEMBL1343584 0.79 CYP3A4 (0.49) ESR2HNF4AALDH1A1BRS3GAA
SCHEMBL29662886 0.78 ESR2 (0.69) ESR2PTPN5ALDH1A1HSD17B10GAA
Water SCHEMBL3178714 0.78 ESR2 (0.69) ESR2PTPN5ALDH1A1HSD17B10GAA
Anthranilic Acid SCHEMBL7609536 0.78 ALDH1A1 (0.62) ALDH1A1HSD17B10GAAKDM4EHPGD
SCHEMBL223 0.78 ESR2 (0.69) ESR2PTPN5ALDH1A1HSD17B10GAA
Anthranilic Acid SCHEMBL28896360 0.78 ALDH1A1 (0.62) ALDH1A1HSD17B10GAAKDM4EHPGD
SCHEMBL10697723 0.77 CYP3A4 (0.47) ESR2HNF4AALDH1A1BRS3GAA
SCHEMBL31299001 0.77 HNF4A (0.56) ESR2HNF4ABCAT2ALDH1A1FABP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2673274-B1 AN IMPROVED PROCESS FOR THE PREPARATION OF AZILSARTAN MEDOXOMIL JUBILANT GENERICS LTD (IN) 2019-07-17 EP disclosed
WO-2016147120-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE AZILSARTAN SMILAX LABORATORIES LIMITED (IN) 2016-09-22 WO disclosed
US-9233955-B2 Process for the preparation of azilsartan medoxomil JUBILANT LIFE SCIENCES, LTD. (IN) 2016-01-12 US disclosed
EP-2673274-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF AZILSARTAN MEDOXOMIL Jubilant Life Sciences Limited (IN) 2013-12-18 EP disclosed
US-20130317230-A1 Process For The Preparation Of Azilsartan Medoxomil Jubilant Generics Limited (IN) 2013-11-28 US disclosed
WO-2012107814-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF AZILSARTAN MEDOXOMIL JUBILANT LIFE SCIENCES LIMITED (IN) 2012-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130317230-A1 Process For The Preparation Of Azilsartan Medoxomil AZI2, KDM4B, KDM4A ESR2 1991/4885HNF4A 655/4885BCAT2 1139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.